Skip to main content

Another Good Week for Biopharma and Diagnostics Stocks: Innovation is Driving Gains

As the market moves with COVID epidemiological data many stocks took a hit on questionable or incomplete news from the WHO on a clinical study in China on Remdesivir; Gilead Sciences stock took a hit on Thursday from $82 but recovered Friday at $79.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.